Skip to main content
. 2022 Jan 6;13:32–45. doi: 10.18632/oncotarget.28168

Figure 1. SHMT2 gene expression is associated with decreased survival and MYCN amplification in neuroblastoma patients.

Figure 1

(A) Kaplan-Meier survival curves created using the R2 genomics analysis application and database shows a decrease in overall survival with increased SHMT2 expression in NB patients. (B) SHMT2 gene expression is significantly higher in patients with MYCN-amplified NB compared to non-MYCN-amplified NB. (C) SHMT2 mRNA expression is increased up to 23.4-fold in the MYCN-amplified cell lines, BE(2)-C and SK-N-DZ, compared to the non-MYCN-amplified cell line, SK-N-AS and SK-N-SH. (D) Immunoblotting demonstrated increased SHMT2 protein expression in the MYCN-amplified cell lines, BE(2)-C and SK-N-DZ, compared to the non-MYCN-amplified cell lines, SK-N-AS and SK-N-SH. (E) Densitometry analysis confirmed a 2.3 to 4.5-fold increase in SHMT2 protein in expression in the MYCN-amplified cell lines, BE(2)-C and SK-N-DZ, compared to non-MYCN-amplified cell lines, SK-N-AS and SK-N-SH.